More patients treated with ligelizumab are angioedema-free compared with omalizumab: Results of a phase II clinical trial
A. Giménez-Arnau, G. Sussman, M. Maurer, E. Hua, K. Kobayashi, R. Janocha, T. Severin, M-M Balp
25th World Congress of Dermatology will be hosted in 2023
